Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of D-Captopril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 7/20 | 1.00 |
| ▸ | REN | P00797 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PEPD | P12955 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Captopril SCHEMBL7983782 | 1.00 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| D-Captopril SCHEMBL675797 | 1.00 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| D-Captopril SCHEMBL2444049 | 1.00 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| D-Captopril SCHEMBL678794 | 1.00 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| D-Captopril SCHEMBL1913521 | 1.00 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| Captopril SCHEMBL4 | 1.00 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| D-Captopril SCHEMBL2444053 | 1.00 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| Captopril SCHEMBL2786691 | 1.00 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| Captopril SCHEMBL5556542 | 0.98 | ACE (0.97) | ACERENKDM4EF2LMNA | |
| Captopril SCHEMBL2489188 | 0.98 | ACE (0.97) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6022885-A | Pyrrolidine and thiazole derivatives with antibacterial and . metallo-.beta-lactamase inhibitory properties | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-08 | — | — | US | claimed |
| CN-109952095-B | Pharmaceutical use of serrate alkane diterpene | 凯楠公爵IP有限责任公司 | 2022-05-03 | — | — | CN | disclosed |
| US-20190282514-A1 | MEDICINAL USE OF SERRULATANE DITERPENES | THE UNIVERSITY OF SYDNEY (AU) | 2019-09-19 | — | — | US | disclosed |
| EP-3509574-A1 | MEDICINAL USE OF SERRULATANE DITERPENES | The University Of Sydney (AU) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018045424-A1 | MEDICINAL USE OF SERRULATANE DITERPENES | THE UNIVERSITY OF SYDNEY (AU) | 2018-03-15 | — | — | WO | disclosed |
| US-8173694-B2 | Therapeutic agent | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| EP-1820501-B1 | Therapeutic agent for depletion of an unwanted protein population from plasma | PENTRAXIN THERAPEUTICS LTD (GB) | 2011-09-14 | — | — | EP | disclosed |
| US-20100173969-A1 | THERAPEUTIC AGENT | PENTRAXIN THERAPEUTICS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-7691897-B2 | R)-1-[6-(R)-2-Carboxypyrrolidin- 1-yl]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid; inhibits ligand binding and also depleting the target protein from the circulation by causing it to be rapidly cleared; the depletion of an unwanted protein population from the plasma of a subject | PENTRAXIN THERAPEUTICS LTD. (GB) | 2010-04-06 | — | — | US | disclosed |
| EP-1820501-A1 | Therapeutic agent for depletion of an unwanted protein population from plasma | Pentraxin Therapeutics Limited (GB) | 2007-08-22 | — | — | EP | disclosed |
| EP-1418905-B1 | THERAPEUTIC AGENT FOR DEPLETION OF AN UNWANTED PROTEIN POPULATION FROM PLASMA | PENTRAXIN THERAPEUTICS LTD (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-20060122124-A1 | Therapeutic agent | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| US-7045499-B2 | Therapeutic agent | PENTRAXIN THERPEUTICS LIMITED (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20060014665-A1 | Complexing protein, especially amyloid, with proline compound ; reducing concentration in blood | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2006-01-19 | — | — | US | disclosed |
| EP-1418905-A1 | THERAPEUTIC AGENT FOR DEPLETION OF AN UNWANTED PROTEIN POPULATION FROM PLASMA | Pentraxin Therapeutics Limited (GB) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003013508-A1 | THERAPEUTIC AGENT FOR DEPLETION OF AN UNWANTED PROTEIN POPULATION FROM PLASMA | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2003-02-20 | — | — | WO | disclosed |
| US-6022885-A | Pyrrolidine and thiazole derivatives with antibacterial and . metallo-.beta-lactamase inhibitory properties | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122124-A1 | Therapeutic agent | ACP1, FCGRT, TTR | ACE 3370/4885REN 1542/4885KDM4E 3935/4885 |
| US-20060014665-A1 | Complexing protein, especially amyloid, with proline compound ; reducing concentration in blood | PRAP1, PRNP, SELP | ACE 429/4885REN 1322/4885KDM4E 4049/4885 |
| US-20100173969-A1 | THERAPEUTIC AGENT | SERPINA6, SERPINB1, NEFM | ACE 545/4885REN 1682/4885KDM4E 4857/4885 |
| US-20190282514-A1 | MEDICINAL USE OF SERRULATANE DITERPENES | GGPS1, FNTA, CYP51A1 | ACE 1301/4885REN 1090/4885KDM4E 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.